Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960343 | 0.91 | FPR2 (0.56) | NPC1RAB9AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2950542 | 0.89 | L3MBTL1 (0.63) | NPC1RAB9AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7153301 | 0.89 | HTR2A (0.54) | NPC1RAB9AL3MBTL1ALDH1A1NAMPT | |
| SCHEMBL4859619 | 0.89 | SMN1; SMN2 (0.56) | NPC1RAB9AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2960922 | 0.88 | L3MBTL1 (0.57) | NPC1RAB9AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6490218 | 0.87 | L3MBTL1 (0.54) | NPC1RAB9AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2949709 | 0.83 | L3MBTL1 (0.58) | NPC1RAB9AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6585359 | 0.81 | NPC1 (0.61) | NPC1RAB9AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2956954 | 0.80 | L3MBTL1 (0.57) | NPC1RAB9AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28750818 | 0.80 | L3MBTL1 (0.56) | NPC1RAB9AL3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754866-B2 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090076254-A1 | NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN SEROTONIN RECEPTORS AND SMALL MOLECULE MODULATORS THEREOF | ARENA PHARMACEUTICALS INC. | 2009-03-19 | — | — | US | disclosed |
| US-7368539-B2 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20050119182-A1 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | US | disclosed |
| CN-1411448-A | Pyrazole derivatives which modulate human 5-serotonin receptors | ARENA PHARM INC (US) | 2003-04-16 | — | — | CN | disclosed |
| US-6541209-B1 | Bioassay; identification of compounds as agonists; use in treatment of diseases and disorders that are related to 5-HT2A and or 5-HT2C serotonin receptors | ARENA PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | disclosed |
| US-6140509-A | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119182-A1 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | HTR2A, HTR3B, HTR3A | NPC1 4146/4885RAB9A 2212/4885L3MBTL1 4160/4885 |
| US-20090076254-A1 | NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN SEROTONIN RECEPTORS AND SMALL MOLECULE MODULATORS THEREOF | HTR2A, HTR3B, HTR3A | NPC1 4146/4885RAB9A 2212/4885L3MBTL1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.